Results 21 to 30 of about 3,021 (181)

Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system

Preventive Medicine, 2019
In 2013, Vermont leaders implemented the "hub-and-spoke" (H & S) system to increase access to medication treatment for opioid use disorder (MOUD). "Hubs" are licensed specialty opioid treatment programs (OTPs) with the authority to dispense buprenorphine/naloxone and methadone.
Richard A. Rawson, Traci Rieckmann, Sarah J. Cousins, Michael McCann, Regina Pearce   +4 more
openalex   +7 more sources

The association between attitudes and the provision of medications for opioid use disorder (MOUD) in United States jails

Drug and Alcohol Dependence Reports, 2023
Opioid use disorder is prevalent among individuals who are incarcerated, yet medications for opioid use disorder (MOUD) are not widely available in United States jails and prisons. Negative staff attitudes across the criminal legal system may prevent MOUD from being provided.
Aly Pfaff, Amy L. Cochran, Jessi Vechinski, Todd Molfenter, Gabriel Zayas‐Cabán   +4 more
openalex   +4 more sources

The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study. [PDF]

Drug Alcohol Depend, 2022
Livingston NA, Davenport M, Head M, Henke R, LeBeau LS, Gibson TB, Banducci AN, Sarpong A, Jayanthi S, Roth C, Camacho-Cook J, Meng F, Hyde J, Mulvaney-Day N, White M, Chen DC, Stein MD, Weisberg R.   +17 more
europepmc   +3 more sources

Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study [PDF]

BMJ Open, 2023
Mistler C, Shrestha R, Gunstad J, Collins L, Madden L, Huedo-Medina T, Sibilio B, Copenhaver N, Copenhaver M.   +8 more
europepmc   +3 more sources

Improving Provider Willingness to Prescribe Medication for Opioid Use Disorder (MOUD)

Background: Opioid use disorder (OUD) accounts for 19% of emergency department (ED) visits nationally. Medication for opioid use disorder (MOUD) has been proven to reduce opioid use, comorbidities, and mortality. Treating patients with MOUD in the community is a proven method for maintaining patients in treatment and improving their health.
Faber, Rebecca J.
openalex   +2 more sources

256 Identifying causes of parenting stress among postpartum mothers receiving medication for opioid use disorder (MOUD) [PDF]

Journal of Clinical and Translational Science
Objectives/Goals: Summarize literature on parenting stress and treatment outcomes among postpartum women with opioid use disorder (OUD). Describe the causes of parenting stress identified by postpartum women who received medication for OUD (MOUD) and service providers.
Mollee K. Steely Smith, Michael A. Cucciare, Melissa J. Zielinski, Nicola A. Conners Edge   +3 more
openalex   +3 more sources

Retention of people who inject drugs enrolled in a ‘medications for opioid use disorder’ (MOUD) programme in Uganda [PDF]

Addiction Science & Clinical Practice
Abstract Background Injection Drug use is associated with increased HIV risk behaviour that may result in the transmission of HIV and poor access to HIV prevention and treatment. In 2020, Uganda introduced the ‘medication for opioid use disorder (MOUD) treatment’ for People who inject drugs (PWID).
Peter Mudiope, Brian Byamah Mutamba, Liz Komuhangi, Joan Nangendo, Stella Alamo, Bradley Mathers, Fredrick Makumbi, Rhoda K. Wanyenze   +7 more
openalex   +4 more sources

Successful Medication for Opioid Use Disorder (MOUD) Program at a Community Hospital Emergency Department [PDF]

Academic Emergency Medicine, 2020
Quentin Reuter, G. Denice Smith, Jamie McKinnon, Joseph D. Varley, Nicholas Jourıles, David C. Seaberg   +5 more
openalex   +3 more sources

The importance of contextually specific support relationships in implementing programs to link people to medication for opioid use disorder (MOUD) treatment during reentry from county jails. [PDF]

Health Justice
McGladrey M, Booty M, Stitzer S, Knudsen HK, Walsh SL, Goetz M, Mattingly H, Lofwall M, Fanucchi L, Oller D, Fallin-Bennett A, Oser CB.   +11 more
europepmc   +3 more sources

Co-delivery of HIV pre-exposure prophylaxis (PrEP) and HIV testing among publicly insured adolescents and young adults (AYA) receiving medication for opioid use disorder (MOUD). [PDF]

Drug Alcohol Depend
Herrera MC, Johnson J, Lim S, Morales KH, Wilson JD, Hadland SE, Metzger D, Wood S, Dowshen N.   +8 more
europepmc   +3 more sources